Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Molecular Partners Ag (MOLN) Capital Expenditures (2021 - 2025)

Historic Capital Expenditures for Molecular Partners Ag (MOLN) over the last 5 years, with Q3 2025 value amounting to $679321.7.

  • Molecular Partners Ag's Capital Expenditures rose 8898.61% to $679321.7 in Q3 2025 from the same period last year, while for Sep 2025 it was $827694.6, marking a year-over-year increase of 2484.37%. This contributed to the annual value of $801374.6 for FY2024, which is 2362.53% up from last year.
  • According to the latest figures from Q3 2025, Molecular Partners Ag's Capital Expenditures is $679321.7, which was up 8898.61% from -$656551.2 recorded in Q2 2025.
  • Molecular Partners Ag's 5-year Capital Expenditures high stood at $1.2 million for Q4 2022, and its period low was -$656551.2 during Q2 2025.
  • Moreover, its 5-year median value for Capital Expenditures was $376.82 (2022), whereas its average is $196004.5.
  • Per our database at Business Quant, Molecular Partners Ag's Capital Expenditures soared by 27437.88% in 2022 and then plummeted by 25649.75% in 2025.
  • Quarter analysis of 5 years shows Molecular Partners Ag's Capital Expenditures stood at $1.0 million in 2021, then grew by 20.72% to $1.2 million in 2022, then crashed by 46.94% to $648541.1 in 2023, then increased by 24.19% to $805422.4 in 2024, then dropped by 15.66% to $679321.7 in 2025.
  • Its Capital Expenditures stands at $679321.7 for Q3 2025, versus -$656551.2 for Q2 2025 and -$498.29 for Q1 2025.